search
Back to results

Effects of a Portfolio Diet on NAFLD in Type 2 Diabetic Patients (MEDEA)

Primary Purpose

Diabetes Type 2, NAFLD

Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Portfolio Diet
MUFA Diet
Sponsored by
Federico II University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Type 2

Eligibility Criteria

35 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • type 2 diabetes
  • non-alcoholic fatty liver disease (evaluated by US)
  • HbA1c <7.5%
  • LDL cholesterol <130 mg/dl

Exclusion Criteria:

  • hypoglycemic therapy with sodium-glucose cotransporter (SGLT-2), pioglitazone and glucagon-like peptide (GLP-1) analogues
  • severe liver and kidney failure
  • recent cardiovascular events (prior 6 months)
  • any other acute/chronic disease (anemia, cancer, BPCO)

Sites / Locations

  • Department of Clinical Medicine and Surgery

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Portfolio Diet

MUFA Diet

Arm Description

The participants will follow a weight-maintaining diet characterized by whole-grain, polyphenol-rich foods, omega 3- rich foods, MUFA-rich foods (protein 18%/total energy, carbohydrates 41%/total energy, fat 41%/total energy, MUFA 26%/total energy, fiber 24 g/1000Kcal) polyphenols 2715/day, omega-3 2.6 g/day and omega-6 9.6 g/day)

The participants will follow a weight-maintaining diet characterized by MUFA-rich food (olive oil) (protein 18%/total energy, carbohydrates 41%/total energy, fat 41%/total energy, MUFA 28%/total energy, fiber 10 g/1000Kcal) polyphenols 376/day, omega-3 1.1 g/day and omega-6 7.4 g/day)

Outcomes

Primary Outcome Measures

Liver fat content
MRI spectroscopy

Secondary Outcome Measures

Liver functionality
Liver enzymes
Blood pressure
Endothelial function
Flow-mediated dilation
Liver fibrosis
Transient Elastography
Biochemical parameters
glucose homeostasis (glucose)
Body composition
bioimpedance analyses (BIA)
lipids
subclinical inflammation
elisa
oxidative stress
urinary isoprostanes
Biochemical parameters
glucose homeostasis (HbA1c)
Biochemical parameters
glucose homeostasis (Insulin)

Full Information

First Posted
October 30, 2017
Last Updated
March 2, 2020
Sponsor
Federico II University
search

1. Study Identification

Unique Protocol Identification Number
NCT03380416
Brief Title
Effects of a Portfolio Diet on NAFLD in Type 2 Diabetic Patients
Acronym
MEDEA
Official Title
Medium-term Effects of a Portfolio Diet on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
April 4, 2017 (Actual)
Primary Completion Date
March 7, 2019 (Actual)
Study Completion Date
December 20, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Federico II University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Patients with type 2 diabetes and non-alcoholic fatty liver disease will be enrolled. According to a parallel design, the participants will be randomized to a Portfolio diet or a monounsaturated fatty acid (MUFA)-rich diet (used as control) for 8 weeks. At the beginning and at the end of the trial, the participants will undergo a MRI spectroscopy to evaluate fatty liver content. Moreover, the participants will undergo a test meal resembling the nutritional composition of the assigned diet to evaluate fasting and postprandial metabolic response.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Type 2, NAFLD

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Care ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
49 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Portfolio Diet
Arm Type
Experimental
Arm Description
The participants will follow a weight-maintaining diet characterized by whole-grain, polyphenol-rich foods, omega 3- rich foods, MUFA-rich foods (protein 18%/total energy, carbohydrates 41%/total energy, fat 41%/total energy, MUFA 26%/total energy, fiber 24 g/1000Kcal) polyphenols 2715/day, omega-3 2.6 g/day and omega-6 9.6 g/day)
Arm Title
MUFA Diet
Arm Type
Active Comparator
Arm Description
The participants will follow a weight-maintaining diet characterized by MUFA-rich food (olive oil) (protein 18%/total energy, carbohydrates 41%/total energy, fat 41%/total energy, MUFA 28%/total energy, fiber 10 g/1000Kcal) polyphenols 376/day, omega-3 1.1 g/day and omega-6 7.4 g/day)
Intervention Type
Other
Intervention Name(s)
Portfolio Diet
Intervention Description
Medium-term (8 weeks ) nutritional intervention
Intervention Type
Other
Intervention Name(s)
MUFA Diet
Intervention Description
Medium-term (8 weeks ) nutritional intervention used as control
Primary Outcome Measure Information:
Title
Liver fat content
Description
MRI spectroscopy
Time Frame
Change from Baseline after 8 weeks
Secondary Outcome Measure Information:
Title
Liver functionality
Description
Liver enzymes
Time Frame
Change from Baseline after 8 weeks
Title
Blood pressure
Time Frame
Change from Baseline after 8 weeks
Title
Endothelial function
Description
Flow-mediated dilation
Time Frame
Change from Baseline after 8 weeks
Title
Liver fibrosis
Description
Transient Elastography
Time Frame
Change from Baseline after 8 weeks
Title
Biochemical parameters
Description
glucose homeostasis (glucose)
Time Frame
Change from Baseline after 8 weeks
Title
Body composition
Description
bioimpedance analyses (BIA)
Time Frame
Change from Baseline after 8 weeks
Title
lipids
Time Frame
Change from Baseline after 8 weeks
Title
subclinical inflammation
Description
elisa
Time Frame
Change from Baseline after 8 weeks
Title
oxidative stress
Description
urinary isoprostanes
Time Frame
Change from Baseline after 8 weeks
Title
Biochemical parameters
Description
glucose homeostasis (HbA1c)
Time Frame
Change from Baseline after 8 weeks
Title
Biochemical parameters
Description
glucose homeostasis (Insulin)
Time Frame
Change from Baseline after 8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: type 2 diabetes non-alcoholic fatty liver disease (evaluated by US) HbA1c <7.5% LDL cholesterol <130 mg/dl Exclusion Criteria: hypoglycemic therapy with sodium-glucose cotransporter (SGLT-2), pioglitazone and glucagon-like peptide (GLP-1) analogues severe liver and kidney failure recent cardiovascular events (prior 6 months) any other acute/chronic disease (anemia, cancer, BPCO)
Facility Information:
Facility Name
Department of Clinical Medicine and Surgery
City
Naples
ZIP/Postal Code
80131
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
35862001
Citation
Della Pepa G, Brancato V, Costabile G, Salamone D, Corrado A, Vitale M, Cavaliere C, Mancini M, Salvatore M, Luongo D, Riccardi G, Rivellese AA, Annuzzi G, Bozzetto L. An Isoenergetic Multifactorial Diet Reduces Pancreatic Fat and Increases Postprandial Insulin Response in Patients With Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care. 2022 Sep 1;45(9):1935-1942. doi: 10.2337/dc22-0605.
Results Reference
derived
PubMed Identifier
35631319
Citation
Costabile G, Della Pepa G, Salamone D, Luongo D, Naviglio D, Brancato V, Cavaliere C, Salvatore M, Cipriano P, Vitale M, Corrado A, Rivellese AA, Annuzzi G, Bozzetto L. Reduction of De Novo Lipogenesis Mediates Beneficial Effects of Isoenergetic Diets on Fatty Liver: Mechanistic Insights from the MEDEA Randomized Clinical Trial. Nutrients. 2022 May 23;14(10):2178. doi: 10.3390/nu14102178.
Results Reference
derived
PubMed Identifier
32448788
Citation
Della Pepa G, Vetrani C, Brancato V, Vitale M, Monti S, Annuzzi G, Lombardi G, Izzo A, Tommasone M, Cipriano P, Clemente G, Mirabelli P, Mancini M, Salvatore M, Riccardi G, Rivellese AA, Bozzetto L. Effects of a multifactorial ecosustainable isocaloric diet on liver fat in patients with type 2 diabetes: randomized clinical trial. BMJ Open Diabetes Res Care. 2020 May;8(1):e001342. doi: 10.1136/bmjdrc-2020-001342.
Results Reference
derived

Learn more about this trial

Effects of a Portfolio Diet on NAFLD in Type 2 Diabetic Patients

We'll reach out to this number within 24 hrs